Cassava Sciences with ticker code (SAVA) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 24 and 14 with a mean TP of 19.33. Given that the stocks previous close was at 7.83 this would indicate that there is a potential upside of 146.9%. The 50 day moving average now sits at 8.38 and the 200 day MA is 6.22. The market cap for the company is $265m. Find out more information at: http://www.cassavasciences.com
Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics and changed its name to Cassava Sciences in March 2019. Cassava Sciences was founded in 1998 and is based in Austin, Texas.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
